While federal efforts to address prescription drug prices have floundered, some states are considering action of their own. The options under consideration mirror those proposed at the federal level, and if enough states adopt them, these policies could have deleterious effects on access and innovation, argues AAF’s Director of Health Care Policy Christopher Holt.

An excerpt:

Many of the policy solutions being advocated to bring U.S. prices in line with other countries’ are punitive in nature, aimed more at punishing pharmaceutical companies for high prices than at meaningfully addressing health care costs. The problem with seeking to punish drug companies for high prices is that in most cases the effects of these policies will ultimately negatively impact American patients most of all.

Read the Analysis